Leap Therapeutics (LPTX) Stock Price, News & Analysis

-0.06 (-1.82%)
(As of 09:42 AM ET)
Today's Range
50-Day Range
52-Week Range
21,164 shs
Average Volume
313,173 shs
Market Capitalization
$82.69 million
P/E Ratio
Dividend Yield
Price Target

Leap Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
252.2% Upside
$11.38 Price Target
Short Interest
4.87% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($2.08) to ($1.15) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.09 out of 5 stars

Medical Sector

767th out of 907 stocks

Pharmaceutical Preparations Industry

360th out of 422 stocks

LPTX stock logo

About Leap Therapeutics Stock (NASDAQ:LPTX)

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

LPTX Stock Price History

LPTX Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
5 Best Biotech Penny Stocks to Invest In
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
LPTX Apr 2024 5.000 call
LPTX Mar 2024 7.000 call
LPTX Jun 2024 1.000 call
LPTX Mar 2024 1.000 call
Recap: Leap Therapeutics Q3 Earnings
See More Headlines
Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$1.50 million
Book Value
$2.35 per share


Free Float
Market Cap
$84.22 million
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Douglas E. Onsi J.D. (Age 55)
    CFO, General Counsel, Treasurer & Secretary, President, CEO & Director
    Comp: $1.04M
  • Mr. Augustine J. Lawlor (Age 67)
    Chief Operating Officer
    Comp: $713.57k
  • Dr. Cynthia A. Sirard (Age 54)
    Chief Medical Officer
    Comp: $708.64k
  • Dr. Jason S. Baum Ph.D. (Age 45)
    Chief Scientific Officer
  • Mr. Mark O'Mahony (Age 53)
    Chief Manufacturing Officer
  • Ms. Christine M. Granfield (Age 56)
    VP and Head of Regulatory Affairs & Quality

LPTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Leap Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LPTX shares.
View LPTX analyst ratings
or view top-rated stocks.

What is Leap Therapeutics' stock price target for 2024?

4 Wall Street analysts have issued 12-month target prices for Leap Therapeutics' shares. Their LPTX share price targets range from $7.00 to $17.50. On average, they anticipate the company's stock price to reach $11.38 in the next year. This suggests a possible upside of 252.2% from the stock's current price.
View analysts price targets for LPTX
or view top-rated stocks among Wall Street analysts.

How have LPTX shares performed in 2024?

Leap Therapeutics' stock was trading at $4.15 on January 1st, 2024. Since then, LPTX shares have decreased by 22.2% and is now trading at $3.23.
View the best growth stocks for 2024 here

When is Leap Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our LPTX earnings forecast

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) posted its quarterly earnings results on Monday, March, 18th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.10.

What ETF holds Leap Therapeutics' stock?

Simplify Health Care ETF holds 529,326 shares of LPTX stock, representing 1.19% of its portfolio.

When did Leap Therapeutics' stock split?

Shares of Leap Therapeutics reverse split on the morning of Wednesday, June 21st 2023. The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Leap Therapeutics own?
Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Key Client Fiduciary Advisors LLC (0.91%).
View institutional ownership trends

How do I buy shares of Leap Therapeutics?

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LPTX) was last updated on 4/25/2024 by Staff

From Our Partners